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ABSTRACT
Objectives: Utilization of multisource biological (off-patent originator and its biosimilar) medicines can
improve the efficiency of resource allocation by 1) generating savings while maintaining health out-
comes or 2) increasing the number of patients treated with more affordable treatments. This study
evaluates the efficiency of the Hungarian biosimilar drug policy on the case of biosimilar infliximab.
Methods: We analyzed the utilization of biologicals in all reimbursed indications of infliximab including
initial therapy of new patients and switching patterns retrospectively based on patient-level payer’s
data between September 2012 and December 2016.
Results: Despite the economic rationale, patent expiry did not manifest in increased utilization of multi-
source infliximab in an access-restricted environment: 1) Patients previously treatedwith original biologicals
were switched mainly to other original biologicals instead of more affordable biosimilar alternatives. 2)
Although some treatment-naive patients started on more affordable multisource infliximab with price
competition, the majority of new patients started on other original biologicals with monopolistic price.
Conclusion: Policy tools and measures should be developed to facilitate first-line use of multisource
biologicals for treatment-naive patients and promoting the use of more affordable multisource biolo-
gicals in case of switching.
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Biological medicines are complex molecules produced through
biotechnological processes [1,2]. Their launch has changed the
treatment algorithms in different disease areas like rheumatology,
dermatology, oncology, gastroenterology, and endocrinology.
Utilization of biological medicines has been increasing constantly
and thesemedicines are gainingmarket share in both volume and
value [3–7]. The price of biologicals is high partly due to increased
development costs stemming from the more complex require-
ments of authorities and manufacturing procedure [8–10].
Sustainability of financing pharmaceuticals is more and
more challenging for third-party health-care payers; hence,
patient access to high-priced biologicals could be limited
[11]. In several lower-income European countries with severe
resource constraints, a wide spectrum of access restrictions
have been implemented to ensure sustainability of pharma-
ceutical expenditures [12–14]. Such restrictions specified by
financial guidelines and protocols include volume restrictions
on the number of patients treated with reimbursed biological
treatment per treatment centers, limited duration of treatment
with reimbursement, or the use of biologicals only in subse-
quent treatment lines after the failure of multiple non-biologic
standard treatments. These public and hidden access restric-
tions, however, may prevent many eligible patients with
chronic diseases from maximizing their health benefits.
Evidence suggests, that standardized utilization figures of
biological medicines for Central and Eastern European (CEE)
countries are less than those in Western or Northern Europe in
cancer and in rheumatoid arthritis [15–17].
In the upcoming years, many biological medicines with high
utilization and significant budget impact are going to losemarket
exclusivity [18,19]. After patient expiry, new biosimilar medicines
come to the market with price discount. Biosimilars with EMA/
FDA approval have similar safety and efficacy profile as the
original biological medicines in case of new patients [20–22]. In
an internal price referencing system, such price discountmay also
incentivize themanufacturer of the off-patent originator product
to decrease price. Therefore, multisource biological medicines
(off-patent originator and its biosimilars) after patent expiry will
become more affordable compared to still patent-protected ori-
ginators maintaining their monopolistic position, but often with
no or only limited added therapeutic value. Multisource biologi-
cals with lower price carry the opportunity to generate savings in
pharmaceutical budget (by maintaining the number of treated
patients) or increase the number of patients treated with more
cost-effective treatments in de-novo cases.
However, full potential of biosimilars in maintenance care
has not been exploited due to concerns raised by different
stakeholders related to the efficacy and safety of switching
patients to biosimilar medicines. The European Medicines
Agency (EMA) has not implemented any regulatory barriers
toward switching of a reference medicine by its biosimilars.
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EMA lets EU member states to set up their own regulation
[23]. It is important to know that recent evidence suggests
that majority of concerns related to switching have been over-
estimated [24] and so increasing evidence supports that single
switch from an originator to a biosimilar medicine under
medical supervision is not associated with significantly
increased risk of immunogenicity for patients [25–27]. From
the societal perspective, the risk of switching under medical
supervision seems to be disproportional compared to the
expected benefit [11,24,28].
The main objective of health policymakers is to maximize
health gain at population-level by improving the allocative
efficiency of the limited resources [29,30]. The value proposition
of off-patent biologicals can be approached from two different
perspectives: If accessibility to original biologicals is not
restricted, after patent expiry multisource biologicals should
generate savings without compromising health outcomes (i.e.
‘disinvestment’ scenario) [31,32]. However, the policy objective
is different in those lower-income European countries where
patient access to original biologicals is restricted. In this case
after patent expiry multisource medicines may provide addi-
tional health gain (i.e. wider patient access) with better cost-
effectiveness ratio (i.e. ‘investment’ scenario) [33].
This study aims to evaluate the efficiency of the Hungarian
biosimilar drug policy by investigating utilization patterns of
biologicals in the indications of infliximab based on data
received from the National Institute of Health Insurance Fund
Management (NIHIFM).
In Hungary the first biosimilar alternative of an originator
biological needs to offer at least 30% price reduction com-
pared to the ex-factory price of the originator, the second
product an additional 10%, and the third product a further
10% [34]. In 2012 an annual blind-bidding process was intro-
duced for erythropoetins and granulocyte colony-stimulating
factors. Based on the results of the bidding process there are
preferred and non-preferred products with different co-
payment levels, products with much higher price than the
preferred alternative are delisted from the reimbursement
system. Monoclonal antibodies are reimbursed through cen-
tral public procurements where the key decisive factor is price.
After the originator infliximab (Remicade) lost its patent
protection in 2013, two biosimilar infliximab alternatives
(Remsima and Inflectra, both manufactured by Celltrion, dis-
tributed by Egis and Hospira/Pfizer, respectively) were granted
marketing authorization for the same indications by EMA in
September 2013 [35–37]. Several studies confirmed the effi-
cacy and safety of biosimilar infliximabs [38,39]. In Hungary,
both biosimilar infliximabs have been reimbursed since
November 2013 [40]. (During the study period, national pro-
curement tenders were won by Inflectra; thus, there were no
utilization records for Remsima in the payer’s database.)
2. Data and methods
Out of eight therapeutic indications of infliximab registered by
EMA (rheumatoid arthritis – RA; adult Crohn’s disease – CD;
pediatric Crohn’s disease – PCD; ulcerative colitis – UC; pediatric
ulcerative colitis – PUC; ankylosing spondylitis – AS; psoriatic
arthritis – PA; psoriasis – P) seven – except PUC – were reim-
bursed during the observational period in Hungary. We ana-
lyzed patient-level utilization data of all biological medicines in
the seven reimbursed indications of infliximab between
September 2012 and December 2016 from the public payer’s
database (NIHIFM). Those patients were involved into this
claims data analysis, who had utilization record of at least one
biologic treatment within the study period. Individual utilization
records were collected and processed by employees of the
NIHIFM and only aggregated data were made available for
academic investigators. Indications were identified through
ICD codes linked to utilization of biological medicine in payer
records. Foreign patients were excluded from the analysis, since
completeness of utilization patterns was less likely for them.
We evaluated the efficiency of the Hungarian biosimilar
drug policy by (1) investigating the uptake of multisource
infliximab after the originator infliximab has lost market exclu-
sivity, (2) assessing prescribing patterns of patients without
prior biological treatment (multisource infliximab vs. patent-
protected biologicals) and (3) analyzing the switching patterns
among different biological medicines.
To answer our research questions, we conducted the fol-
lowing analyses: (1) We prepared a longitudinal analysis of the
number of patients on biological medicines in each reim-
bursed indication of infliximab. We aggregated independent
patient utilization records at monthly-level and we calculated
number of patients on treatment. (2) We calculated the market
share of multisource infliximab compared to other patent-
protected biologicals in the initial biological therapy of treat-
ment-naive patients. (3) We calculated and compared switch-
ing rates a) from original infliximab to biosimilar infliximab; b)
from original infliximab to other patented biologicals; c) from
other patented biologicals to multisource infliximab; d)
between other patented biologicals.
Initial assessment of utilization patterns suggested to cre-
ate and separately analyze two indication clusters, based on
the number of reimbursed active substances per indication
(Cluster 1: Infliximab and one other original biological, Cluster
2: Infliximab and at least three other original biologicals)
(Table 1).
Article highlights
● The value proposition of off-patent pharmaceuticals can be
approached from two different perspectives based on accessibility
of patients to original medicines before the patent expiry. Hence,
lower priced biosimilar alternatives can either generate savings in the
pharmaceutical budget or increase the number of patients treated by
biologicals without the need for extra budget.
● In lower-income countries with economic constraints (such as coun-
tries in Central and Eastern Europe), biosimilar drug policies should
incentivize the utilization of more affordable multisource biological
pharmaceuticals to improve patient access.
● In Hungary, the biosimilar policy did not result in increasing utiliza-
tion of more affordable multisource biological medicines compared
to other original biologicals in the indications of infliximab.
● Policymakers may choose from several options in different areas,
including public administration and clinical guidelines, to facilitate
biosimilar use. The efficiency of policy interventions should be mon-
itored by reviewing the initial therapy of new patients and switching
patterns.
2 A. HARSÁNYI ET AL.
3. Results
3.1. Longitudinal patient numbers in each reimbursed
indication
Results of the longitudinal data analysis provide an overall
picture about major utilization trends of biological medicines
within the reimbursed indications of infliximab (Figure 1). In
case of Cluster 1 the original infliximab had high market share
before the patent expiry. In UC and PCD infliximab was the
dominant choice compared to adalimumab. Regarding UC, the
average monthly market share of original infliximab was 81.7%
(decreasing from 100% to 63% at patent expiry); while
adalimumab had an 18.3% average market share increasing
from 0% to 37% at infliximab patent expiry. As for PCD, the
average monthly market share of original infliximab before
patent expiry was 100% since it was the only reimbursed
biological medicine within the indication. In case of CD, inflix-
imab and adalimumab had almost the same average market
share at patent expiry, 51% and 49%, respectively. Interestingly,
after patent expiry, the market share of multisource infliximab
showed a decreasing trend in each indication. As for Cluster 2,
infliximab utilization was much less dominant even before
patent expiry: the average monthly market share was in the
range of 9% and 27% in different indications. Furthermore, the
Table 1. Number of active biological substances in the reimbursed indications of infliximab.
Cluster
Number of reimbursed active
biological substances List of reimbursed active biological substances Indication
Cluster 1 Infliximab and one other original
biological
infliximab adalimumab Ulcerative Colitis Adult Crohn’s Disease
Pediatric Crohn’s Disease
Cluster 2 Infliximab and at least three other
original biologicals
infliximab adalimumab etanercept golimumab Ankylosing Spondylitis Psoriatic Arthritis
infliximab adalimumab etanercept ustekinumab Psoriasis
infliximab abatacept adalimumab certolizumab pegol etanercept
golimumab rituximab tocilizumab
Rheumatoid Arthritis
Figure 1. Number of patients treated with biological medicines in the reimbursed indications of infliximab.
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utilization of multisource infliximab was even further reduced in
Cluster 2 after the original infliximab lost its market exclusivity.
3.2. Treatment for new patients
Table 2 contains the average market share of reimbursed
biologicals (original and biosimilar infliximab and other, still
patent-protected biologicals) before and after patent expiry.
Calculations were done to appraise the prescribing patterns in
biological treatment-naive patients before and after the
patent expiry of infliximab.
In Cluster 1, before patent expiry infliximab was the domi-
nant choice for biological treatment-naive patients in UC
(59.6%), in CD (49.7%) and in PCD (100.0%). After patent expiry,
the overall utilization of multisource infliximab (i.e. the sum of
original and biosimilar infliximab utilization) increased to 63.8%
in UC, and to 51.3% in CD. On the contrary, a declining trend
was observable in case of PCD, where utilization of multisource
infliximab decreased to 35.5% after patent expiry. (Originator
infliximab maintained a market share between 13.5% and
17.1% in all three indications even after patent expiry.)
As for the indications in Cluster 2 original infliximab utiliza-
tion was marginal compared to Cluster 1, both before and
after patent expiry. In RA, the market share of original inflix-
imab was only 2.6% during the patent protection period,
interestingly price erosion due to patent expiry did not affect
positively the utilization of more affordable multisource inflix-
imab. In AS and P higher utilization of infliximab was observed
before patent expiry (11.0% and 8.9%, respectively); however,
the utilization of more affordable multisource infliximab after
patent expiry decreased further to 5.2% and 3.0%, respec-
tively. In PA a slight increase from 6.3% (original infliximab)
to 6.9% (multisource infliximab) was found after the market
entry of biosimilar infliximab.
3.3. Switching patterns
Switching patterns of biologicals in different indications are
presented in Table 3. As for Cluster 1, 70-76% of switches
occurred from infliximab to the other, still patented biological
medicine. In case of Cluster 2, proportion of switching from
infliximab to another still patent protected original biological
was much smaller, between 9%-23% in different indications.
Switching from original infliximab to biosimilar infliximab hap-
pened rarely. In case of Cluster 1 switching from original infliximab
to biosimilar infliximab occurred only in 7-16% of switches. In
those indications with three or more patented biologicals
(Cluster 2), only 0%-3% of patients were switched from original
infliximab to the biosimilar alternative. Patients in both clusters
were switched mainly to other, still patented original biologicals.
There were only a few cases when patients switched from
other patented biologicals to multisource infliximab in Cluster 1,
with more patients switching to the biosimilar alternative com-
pared to those switching to the original infliximab. In Cluster 2
the proportion of switching from other patented biologicals to
multisource (original and biosimilar) infliximab was between 1%-
5% and 1%-12%, respectively, in different indications. In Cluster 2
Table 2. Average share of initial biological therapy for treatment-naive patients in different indications before and after patent expiry of infliximab.









Infliximab and one other original
biological
Ulcerative Colitis 59.6 N/A 40.4
Adult Crohn’s Disease 49.7 50.3
Pediatric Crohn’s Disease 100.0 0.0
Infliximab and at least three other
original biologicals
Rheumatoid Arthritis 2.6 97.4
Ankylosing Spondylitis 11.0 89.0
Psoriasis 8.9 91.1
Psoriatic Arthritis 6.3 93.8
After Patent Expiry
2013.11. – 2016.12.
Infliximab and one other original
biological
Ulcerative Colitis 13.5 50.3 36.3
Adult Crohn’s Disease 14.3 37.0 48.7
Pediatric Crohn’s Disease 17.1 18.4 64.6
Infliximab and at least three other
original biologicals
Rheumatoid Arthritis 0.4 1.2 98.4
Ankylosing Spondylitis 1.1 4.1 94.8
Psoriasis 1.4 1.6 97.0
Psoriatic Arthritis 1.5 5.4 93.1
Table 3. Switching patterns in the reimbursed indications of infliximab (2012.09. – 2016.12.).















Total switch per indication 255 376 50 2194 672 489 278
Share of switch from infliximab among total switch (%) 76 70 70 9 23 23 16
Total switch from original infliximab 164 237 28 181 141 106 39
Share of switch from original infliximab (%) to biosimilar infliximab 16 15 7 0 1 0 3
to other original biological(s) 84 85 93 100 99 100 97
Total switch from other patented original biological(s) 36 79 12 2002 516 375 233
Share of switch (%) from other
original
biological(s)
to original infliximab 25 34 0 1 4 5 2
to biosimilar infliximab 75 66 100 1 10 4 12
between other original biologicals N/A N/A N/A 98 86 91 86
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patients were dominantly switched from a patented biological to
other, still patented biologicals (86%-98%).
4. Discussion
Results of the longitudinal analysis demonstrated an increasing
utilization of biologicals during the study period in all indications.
This implicitly confirms the existence of hidden access barriers
toward biologic medicines with high budget impact in Hungary
[14]. Economic rationale suggests that increased utilization of
more affordable, multisource biologicals is an appropriate policy
intervention to tackle access barriers in countries with limited
resources [41]. However, as suggested by the case of infliximab in
Hungary, often other patent-protected original biologicals con-
tribute to the increased utilization of biologicals instead of the
more affordable multisource products.
If an active substance loses its market exclusivity and other
reimbursed original biologicals do not have-, or have only
minimal proven added benefit compared to the multisource
alternatives, multisource biologicals are more cost-
effective; thus, they should be recommended as first-line ther-
apy for treatment-naive patients in financial protocols describ-
ing how medicines with reimbursement can be prescribed
[14]. In this case all other, still patent-protected biologicals
should be used in second-line treatment, after the failure of
the multisource product. This would be highly similar to many
other diseases with great public health burden, where small
molecule generic medicines are the first-line treatments
[42,43], and innovative therapies are used only in latter treat-
ment lines. However, despite the economic rationale, the
increased utilization of multisource infliximab was not
observed either in Cluster 1 or in Cluster 2; moreover, results
of Cluster 2 indicates that physicians in 95% of the cases do
not even try to initiate the multisource infliximab as a first-line
treatment for naive patients. This result indicates that market
launch of infliximab biosimilars in Hungary was not translated
to increased utilization of more affordable multisource biolo-
gicals in the field of monoclonal antibodies.
In case of maintenance care patients, a single switch from
the original biological to its more affordable biosimilar alter-
native should be promoted under medical supervision [41].
Also, in case of a treatment failure on patented biologicals,
switching patients to more affordable multisource biologics
with competing price could increase allocative efficiency.
However, our real-world utilization data indicated that physi-
cians had limited concerns with switching their patients
between other original biologicals, but they were reluctant
to switch their patients to multisource infliximab, if there
were any other alternative patented biologicals on the reim-
bursement list (in case of Cluster 2).
4.1. Study limitations
Several factors may influence the utilization pattern of different
biologicals, hence limit the generalizability of our findings. We
could not obtain information on actual prices, and so we did
not take into account confidential price discounts in our analy-
sis. We also have not considered the impact of perceived
differences in relative effectiveness and different administration
route (i.e. subcutaneous vs. intravenous) on therapy selection of
biological therapies. Finally, observations in autoimmune dis-
eases may not be transferable to other therapeutic areas, such
as malignancies.
5. Conclusion
Our results suggest that the full potential of biosimilars has
not been exploited in Hungary yet. In lower-income countries
such as the CEE countries, successful biosimilar drug policies
should incentivize the utilization of more affordable multi-
source biological pharmaceuticals to improve patient access.
6. Expert commentary
In line with conclusions of other recent studies [44–46], we
believe that education of policymakers, health-care profes-
sionals and patients on the opportunity cost of not using
biosimilars would be essential in lower-income countries to
improve patient access biological medicines.
A recent publication [41] recommended policy interven-
tions in four different areas – 1) public administration, 2)
clinical guidelines, 3) evidence base of policymaking and 4)
management of uncertainty – to maximize the social benefits
of multisource biologicals. We evaluated based on our study
findings whether these recommendations (marked with italic)
are applied in Hungary. Lessons learned from this study may
be generalizable to other lower-income countries as well.
6.1. Recommendations for public administration
● Policymakers should develop incentives and administrative
tools to enhance the increased utilization of more affordable
medicines: analysis of the biologicals’ utilization data in the
indications of infliximab suggests that the current
Hungarian biosimilar policy could not facilitate the uptake
of more affordable multisource biologicals effectively.
● Simplified ‘fast-track’ inclusion process should be provided
for biosimilars: In Hungary, biosimilar infliximab brands
entered the market on 1 November 2013. Despite the fast-
track reimbursement decision and that biosimilar inflixi-
mab was already available on the positive list, the first
utilization record was detected only at the end of
May 2014, due to the slow tendering procedure. The
opportunity cost of 6-month delay in the utilization of
biosimilar infliximab could be considered fairly significant.
6.2. Recommendations for clinical guidelines
● Multisource biologicals should be used in first line among
biological therapies: When multiple reimbursed biologi-
cals are available within a therapeutic area, priority order
of different therapies should be clearly determined in
a financial protocol (i.e. mandatory clinical guideline
developed jointly by clinical societies and payer, which
considers both clinical and economic aspects) in order to
facilitate the increased uptake of more affordable multi-
source biological medicines. Off-patent products on
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a competitive market with access restrictions may pro-
vide more health gain for the same budget by increasing
the number of patients treated with biologicals. Based
on the current financial protocols, NIHIFM considers that
there are no notable differences between the available
reimbursed biologicals in terms of efficacy and safety;
however, the financial protocol does not consider the
price differential between single source medicines with
monopolistic price and multisource medicines with price
erosion. Consequently, the more affordable multisource
infliximab was not a dominant choice as a first-line treat-
ment for prescribers and patients.
● Single switch from original to the more affordable biosimi-
lar alternatives under medical supervision should be man-
datory: During the research period of our analysis
(2012–2016), switching from maintenance treatment to
the preferred tender winner brand was not mandated or
at least incentivized by the public payer. Using the lower
priced biosimilar infliximab was only mandated for bio-
logical treatment-naive patients, but not for patients on
maintenance therapy.
6.3. Recommendations for evidence-based policymaking
and for managing uncertainty
● Collect pharmacovigilance data and develop risk-
management plans due to increased risk of immunogeni-
city: Currently, NIHIFM has highly limited resources to
manage the complex tasks of 1) evidence-based phar-
maceutical policymaking and 2) monitoring the impact
of previous policy decisions in the arena of biological
products. In the last years, there have been multiple
restructuring and cutbacks in all fields of the public
administration in Hungary. As a consequence, turnover
of human resources at the public payer is outstanding,
and analytical capacities are constantly decreasing. Lack
of trained experts prevents collecting real-world evi-
dence on the consequences of switching and applying
outcomes-based risk-sharing agreements to manage any
potential uncertainties related to switching.
7. 5-years view
Evidence-based pharmaceutical policy has become the stan-
dard approach for investment decisions of health care includ-
ing coverage decisions of new pharmaceuticals. On the
contrary, disinvestment decisions like the rational use of off-
patent pharmaceuticals including biosimilars are rarely sub-
stantiated with convincing scientific evidence. In the next five
years, more policy research is needed to facilitate effective
biosimilar policies. Decision-makers are expected to recognize
that the opportunity cost of suboptimal biosimilar medicine
policies is even higher in countries with limited resources and
poorer overall health status. Countries with access restrictions
toward modern medicines should not approach biosimilars
only from a disinvestment perspective. Payers are expected
to be more proactive in promoting rational use of multisource
biologicals as preferred first-line treatments for naive patients.
Switching patients on maintenance treatment to biosimilars
are expected not to be prevented based on hypothetical
concerns. Manufacturers of biosimilar products are expected
to be more involved in managing uncertainties related to
biosimilars and increasingly taking over risks of payers.
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